Yazar "Doğu, Mehmet Hilmi" seçeneğine göre listele
Listeleniyor 1 - 16 / 16
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe A MALT LYMPHOMA PRESENTING WITH PRIMARY DIFFUSE RENAL INVOLVEMENT(Eskişehir Şehir Hastanesi, 16 Ekim 2023) Doğu, Mehmet Hilmi; Karışmaz, Abdülkadir; Suyani, Elif; Huq, Erdem Gülben; Altındal, Sermin; Serin, İstemi; Yokuş, OsmanThe involvement of kidney in marginal zone lymphoma (MZL) is not a frequent condition. Seventy-seven year old female presented with renal failure. Renal biopsy revealed diffuse lymphoid infiltration replacing the normal renal tissue. Immunohistochemical staining was CD20, CD38, kappa, IgD positive and CD3, lamda, cyclin D1, CD5, CD23, CD43, lambda negative. Ki-67 was 10% positive. The patient was diagnosed as MALT type MZL. Body 18Fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) performed for staging revealed diffuse FDG uptake in both kidneys and no lymphadenopathy was detected. Bone marrow aspiration and biopsy were normal. Rituximab-bendamustin chemotherpy regimen was started. In conclusion, this is the first case of MALT lymphoma involving kidney diffusely which requires rapid diagnosis and treatment to prevent irreversible loss of renal functions.Öğe The association between red cell distribution width and bone marrow fibrosis in patients with Philadelphia-negative myeloproliferative neoplasms(TR- Dizin, 2022) Aslan, Ceyda; Karışmaz, Abdülkadir; Eren, Refet; Altındal, Şermin; Doğu, Mehmet Hilmi; Suyanı, ElifObjective: Red cell distribution width (RDW) was shown to be increased in primary myelofibrosis (PMF) patients and it is intriguing whether RDW could be used instead of biopsy in predicting presence of bone marrow fibrosis (BMF) to some extend in Philadelphia-negative myeloproliferative neoplasms (MPNs) comprising polycytemia vera (PV), essential thrombocytosis (ET) and PMF. Our aim is to evaluate the relationship between BMF degree and RDW values in patients with MPNs. Method: We retrospectively reviewed the data of 118 patients, who were followed with the diagnosis of MPNs at our Hematology Clinic between 2010 and 2017. Results: 52 patients had PV, 60 had ET, 4 had PMF and 2 had unclassifiable MPN. Twentynine (24.6%) patients were with grade 0 and grade 1 reticulin fibrosis were considered to be free of BMF, and the remaining 89 (75.4%) patients with ? grade 2 reticulin fibrosis were considered to have BMF. The median RDW value was 14.6% (range 12,4-23,1%). The median RDW value revealed with 14.1% (range, 12.4-17.8) in patients without BMF and 15% (range, 12.4-23.1) in patients with BMF (p=0.054). In subgroup analysis of 8 patients with advanced BMF of grade 3, the median RDW value was 18.45% (range, 16.4-23.1) and it was 14.45% (range, 12.4-23) in the remaining 110 patients (p=0.008). Conclusion: Although the present study does not provide a precise conclusion about the association between RDW and BMF, it seems that increased RDW can point out the presence of advanced BMF in patients with MPNs.Öğe Brentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data(Hitit Üniverstesi Tıp Fakültesi, 23.07.2024) Darçın, Tahir; Serın, Istemi; Ugur, Mehmet Can; Ekinci, Omer; Hindilerden, Ipek Yonal; Akpınar, Seval; Hacibekiroglu, Tuba; Demircioğlu, Sinan; Gültürk, Emine; Albayrak, Murat; Aydogdu, Ismet; Dal, Mehmet Sınan; Doğu, Mehmet Hilmi; Namdaroglu, Sinem; Doğan, Ali; Nalcaci, Meliha; Turgut, Burhan; Başcı, Semih; Altuntas, FevziObjective: We present data of patients with relapsed/ refractory T cell lymphomas treated with brentuximab vedotin (BV) in real-world practice. Material and Method: This study is an observational, multi-center, retrospective study. The data of patients (n=17) treated with BV alone from January 2014 until July 2020 in thirteen centers from Turkey were collected. Results: Bv was given as salvage chemotherapy to 17 patients with median age of 53. Nine (52.9%) patients had diagnosis of peripheral T cell lymphoma, not otherwise specified; 8 (47.1%) patients had anaplastic large T cell lymphoma. The median follow-up of the cohort was 20 months. Nine (52.9%) patients had complete response, 5 (29.5%) had partial response, 3 (17.6%) had progressive disease. The safety results aligned with the established profile of BV, included 2 pneumonia and 1 thrombocytopenia with grade 4. The median progression free survival of the cohort was 10 months. BV cycle and response to BV therapy were found to have an effect on the univariate analysis. Conclusion: In patients with relapsed/ refractory T cell lymphomas, BV seems to have convincing antitumor activity with favorable safety profile.Öğe Efficacy of the lactate dehydrogenase (LDH)/lymphocyte ratio (LLR) to reduce the need for X-ray in pregnant patients with COVID-19(De Gruyter Open, 2022) Doğu, Sevilay Yavuz; Serin, İstemi; Doğu, Mehmet Hilmi; Güleroğlu, Filiz Yarşılıkal; Dane, CemPregnancy carries a significant risk for coronavirus disease-2019 (COVID-19) due to natural immunosuppression. A previous study from our center has shown that the lactate dehydrogenase (LDH)/lymphocyte ratio (LLR) can be used in the early diagnosis of COVID-19 and predicting mortality. Based on this, we aimed to determine the effect of LLR on early detection of critical pregnant women and mortality in COVID-19. The data of 145 patients who were admitted to our hospital between March and December 2020; diagnosed with COVID-19 and hospitalized, were retrospectively analyzed. The median gestation period was 31 weeks (range: 5-41), 30.3% (n: 44) gave birth and 68.3% (n: 99) were pregnant. Median LLR was 0.13 (range: 0.04-0.70). The rate of cough (47% vs. 22.8%; p=0.003) was found to be high in patients with LLR>0.13. The patients were divided into subgroups. The proportion of patients without active complaints was higher in the Q1, followed by the Q4. The proportion of patients with an initial complaint of cough increased as LLR from Q1 to Q4, the distribution of other complaints did not differ between the quartiles. The higher rate of cough in the group with high LLR indicates that it may be an important indicator of lung involvement during pregnancy. The highest rate of non-treatment follow-up in the lowest LLR group proved that the LLR value at the time of diagnosis can be used as an important clinical marker in pregnant women. © 2022 De Gruyter. All rights reserved.Öğe Evaluation of the relationship between bone marrow changes and hemogram findings in HIV-positive patients(Galenos publ house, 2025) Karışmaz, Abdulkadir; Cavdar, Vahit Can; Doğu, Mehmet Hilmi; Aslan, Ceyda; Sarı, Nagehan Didem; Erdem Huq, Gülben; Eren, RafetAim: This study aimed to evaluate the relationship between bone marrow (BM) changes and initial laboratory findings in Human immunodeficiency virus (HIV)-positive patients, focusing on hematopoietic system alterations such as myeloid hyperplasia, erythroid hyperplasia, and megakaryocyte activity. Materials and Methods: A total of 57 HIV-positive patients were included in this retrospective study. BM findings, including cellularity, plasma cell ratio, reticulin fiber ratio, and specific features such as myeloid and erythroid hyperplasia, were analyzed. Initial laboratory parameters, including white blood cell (WBC), hemoglobin (HGB), hematocrit (HCT), platelet, and CD4 counts, were assessed. Results: Significant positive correlations were observed between cellularity and WBC (r=0.40, p=0.005), monocyte (r=0.40, p=0.005), and CD8 counts (r=0.32, p=0.02). Plasma cell ratio showed negative correlations with HGB (r=-0.35, p=0.01), HCT (r=-0.35, p=0.01), and albumin (ALB) (r=-0.50, p<0.001). Reticulin fiber ratio was negatively correlated with WBC (r=-0.30, p=0.03), HGB (r=-0.32, p=0.02), and ALB (r=-0.35, p=0.008). Conclusion: BM changes in HIV-positive patients, such as myeloid and erythroid hyperplasia, are associated with significant alterations in peripheral blood parameters, highlighting the importance of comprehensive hematological evaluations in this population. These findings contribute to a better understanding of HIV-related hematopoietic dysfunction and its clinical implicationsÖğe Follicular lymphoma: frequency and timing of treatment: single center experience(Galenos publishing house, 2025) Karışmaz, Abdulkadir; Can Cavdar, Vahit; Serin, İstemi; Doğu, Mehmet Hilmi; Aslan, Ceyda; Eren, RafetIntroduction: This study aimed to investigate how often follicular lymphoma (FL) occurs in patients diagnosed with non-Hodgkin lymphoma (NHL). Additionally, we investigated whether patients with FL required treatment, and if so, whether the need for treatment arose at the initial diagnosis or during subsequent follow-up periods. Methods: Six thousand five hundred sixty patients diagnosed with NHL or chronic lymphocytic leukemia were reached, and healthy data were obtained from 1,719 of them. Data from 176 patients diagnosed with FL were evaluated. Demographic information (age, gender) of the patients was collected. The classifications were grouped by taking into account World Health Organization data, the histological subtype of the tumor, gender and need for treatment were evaluated. Results: Among the patients, 55.1% (n=97) were men and 44.9% (n=79) were women. The median age of those with FL was 50 years, with ages ranging from 18 to 87. When looking at histological subtypes, the FL accounts for 10.2% of cases (n=176). The proportion of patients requiring treatment was 70.9% (125), and the proportion of patients followed up without treatment was 27.8% (49). Of the patients who needed treatment, 57.1% (n=101) required it at the time of diagnosis and 13.6% (n=24) during follow-up. Conclusion: FL, making up around 20% of all NHL, is the second most prevalent type of lymphoma in adults. The incidence, as well as the gender and age distribution, of FL can differ across populations. This may be related to ethnicity, geographical conditions, and socioeconomic status. In addition, the proportion of patients requiring treatment may also vary. When all these are taken into account, social differences are some of the main determinants in the approach to FL.Öğe Hemolytic anemia and plasma exchange(Elsevier Ltd, 2021) Serin, Istemi; Doğu, Mehmet HilmiHemolytic anemia is a disease caused by autoantibodies and resulting in various complaints and clinical symptoms. In about half of cases, the cause of autoimmune hemolytic anemia can not be determined. Corticosteroids are the first-line treatment option for warm autoantibody-related hemolytic anemia. In patients who develop steroid side effects or do not respond adequately, other immunosuppressives may be preferred. In case a rapid response is required or fulminant hemolysis occur, human immunoglobulins (IVIGs) may be added to treatment. Finally, plasma exchange (PE) may additionally be utilised. The essence of PE is based on the removal of immune complexes, protein-bound toxins, autoantibodies and high molecular weight solutes and protein-bound solutes. The main clinical aim of the removal of solutes is usually to gain a faster response than immunosuppressive therapy. Studies related to hemolytic anemia and PE are usually based on case reports. Our case report is about a patient with severe IgG subtype hemolytic anemia. The treatment was started with 1 mg/kg methylprednisolone; to which there was no response with weekly rituximab 375 mg/m2 and IVIG administered. Because of unresponsiveness to all of the immunosuppresives, a total of 5 sessions of PE were added to the treatment procedure every other day. After these sessions, the requirement for transfusions has decreased and the patient underwent splenectomy. The patient is currently being followed up only on oral cyclosporine and the last hemoglobin level was 14.7 g /dl. In severe and refractory anemia, especially in the case of cardiovascular imbalance in fulminant hemolysis, PE may be preferred as a third series option after immunosuppressive treatments and play a role as a bridge to splenectomy.Öğe Mucormycosis in hematologic malignancies: clinical follow-up and treatment results(ISTANBUL TRAINING & RESEARCH HOSPITAL, 2021) Sari, Nagehan Didem; Serin, Istemi; Kirgezen, Tolga; Doğu, Mehmet HilmiIntroduction: Mucormycosis is an aggressive-progressive invasive fungal infection caused by mold fungi in the division of mucorales of the zygomycetes class with high mortality, and is the most common fungal infection in patients with hematologic malignancies. Methods: This study retrospectively evaluated patients with mucormycosis diagnosis between January 2015 and December 2019, including demographic features, hematologic diseases and comorbidities, radiological evaluations, symptoms and signs, treatments, and outcomes. Results: Maxillofacial 9/19 (47.37%) of patients and 10/19 (59.9%) rhinoorbital mucor. Hematologic malignancy was observed in 15 (78.95%) patients, whereas others had additional pre-disposing factors, such as diabetes mellitus and chronic renal failure. The most common find-ings were persistent fever, mucopurulent nasal flux, and periorbital edema. Endoscopic sinus surgery + medication was administered in 12/19 (62.2%) patients and antifungal therapy in 7/19 (37.8%). In addition, 15/19 (79.95%) patients died and 4/19 recovered with sequela. Conclusion: The first large-scale mucormycosis study from our country will guide in determining the treatment algorithm. Effective and early surgery and antifungal application reduce mortality in mucormycosis by early diagnosis and multidisciplinary approach, without bone destruction in the paranasal sinus computed tomography with recurrent fever and earlystage sinusitis finding by performing a biopsy.Öğe A new FLT3 inhibitor with two cases: the gilteritinib experience(E-CENTURY PUBLISHING CORP, 2021) Serin, Istemi; Doğu, Mehmet Hilmi; Huq, Gulben Erdem; Yokus, OsmanIntroduction: In acute myeloid leukemia (AML), a heterogeneous group of leukemias, there are various factors to determine prognosis. Among these prognostic factors, cytogenetic results are increasing in importance day by day. FLT3 mutations are among the most common molecular abnormalities in AML, patients with recurrent or refractory (R/R) AML with this mutation have a low response rate to salvage therapy. Gilteritinib has activity against FLT3, ALK and AXL. This article shall present two cases, for which Gilteritinib was used, a new FLT3 inhibitor, and the results of the treatment. Case 1: A 52-year-old female patient presented to the emergency clinic with weakness and fever. In initial biochemical analysis, leukocyte was 104000/mm(3). Peripheral smear contained diffuse myeloid blastoid cells, peripheral blood flow cytometry also supported the AML M0-1 phenotype. The bone marrow biopsy aspiration performed on the 14th day of induction "3+7" treatment, contained diffuse blastic infiltrate and supported refractory disease. In addition to the FLAG-IDA salvage regimen, 120 mg/day Gilteritinib was also started. Bone marrow aspiration performed on the 28th day of salvage therapy was compatible with remission. Case 2: 53 years old male patient with also no comorbidity other than known hypertension. In the initial biochemical analysis of the patient, leukocyte was 156000/mm(3), platelet 58000/mm(3) and hemoglobin 7.6 g/dl. Peripheral blood flow cytometry supported the AML M5 phenotype, whose peripheral smear showed diffuse monoblastoid cells. On the 14th day of the patient's 3+7 induction treatment, the control bone marrow aspiration showed diffuse blast infiltration and was considered refractory, FLAG-IDA salvage therapy with again 120 mg/day Gilteritinib per oral were started. On the 28th day, control bone marrow aspiration was evaluated as remission. Discussion and conclusion: Unlike other FLT 3 inhibitors, Gilteritinib has been shown to be a highly effective agent in R/R AML with FLT3 mutations. Being the first data to be reported from Turkey, we think it would be quite guiding the titular.Öğe Quality of Life assessment with EORTC QLQ in patients with hodgkin lymphoma: multicenter study(Tr dizin, 2022) Gemici, Ali Ihsan; Serin, İstemi; Erol, Vedat Buğra; Doğu, Mehmet Hilmi; Karakuş, VolkanAim: The aim of our study is to obtain data on the quality of life (QoL) in Hodgkin lymphoma (HL) patients in a representative sample of the general population of Turkey with the help of the EORTC QLQ-C30 and QLQ-HL27 questionnaires. Material and Methods: A total of 68 patients from seven different centers diagnosed with HL between 2018-2020 were included in the study. The questionnaires were answered cross-sectionally by the patient under the control of a physician in the centers participating in the study. Results: Out of 68 patients, 42.6% (n=29) were female and 57.4% (n=39) were male. The ages of the patients ranged from 18 to 74 years, with a mean of 42.10±16.62 and with a median value of 40 years. There was no significant difference between age subgroups in terms of QLQ-C30 global health status/ QoL, functional or symptom scales and HL27 SB, PC, EI and WF scores (p>0.05, for all). It was determined that the constipation scores of females were higher than the scores of males (p=0.041). No statistically significant difference was found in terms of HL27 SB, PC, EI and WF sub-dimension scores according to gender (p>0.05). Conclusions: There was only a statistically significant difference in terms of QLQ-C30 constipation sub-dimension scores according to gender. The constipation scores of females were higher than the scores of men. More detailed and large population studies are needed to reveal the effectiveness of QoL assessment in HL patients.Öğe Real life experience regarding clinical characteristics and treatment outcome in non-cutaneous peripheral t cell lymphomas: A multicenter study of Turkish hematology research and education group (threg)(Gelanos, 2022) Kayıkçı, Ömür; Özgür, Mehtap; Sarı, İsmail; Demirkan, Fatih; Beyan, Cengiz; Güven, Çetin; Vural, Filiz; Yılmaz, Mehmet; Öztürk, Erman; Akpınar, Seval; Eser, Bülent; Gündüz, Mehmet; Büyükaşık, Yahya; Payzın, Bahriye; Yıldırım, Rahşan; Doğu, Mehmet Hilmi; Özkan, Atilla; Kelkitli, Engin; Tekgündüz, EmreObjective: Peripheral T-NK-cell lymphomas (PTCL) are uncommon, quite heterogeneous group of disorders, and representing only 10–15% of all non-Hodgkin lymphomas (NHL). Although both molecular and clinical studies have been increased in recent years, we have still little knowledge regarding the real-life practice on PTCLs. In this study, we aimed to investigate the clinical characteristics and treatment outcomes in a large population-based cohort of patients presenting with systemic non-cutaneous PTCL patients. Material and methods: We conducted a multicenter retrospective analysis of 190 patients consecutively diagnosed and treated with non-cutaneous PTCLs between 2008 and 2016. Results: Considering all first-line treatment combinations, the overall response rate (ORR) was 65.9% with 49.4% complete remission (CR) (n=81) and 16.5% partial response (PR) (n=27). The 5-year OS and EFS rates were significantly different between the transplant and non-transplant groups (p<0.01, and p=0.033), respectively. Conclusion: Current retrospective large real-life data analysis of Turkish experience regarding the non-cutaneous PTCL patients showed consistent results compared to other unselected PTCL cohorts, with some minor differences in terms of survival and transplantation outcomes compared to existent experience. The long-term outcome of patients who received autologous hematopoietic cell transplantation as part of upfront consolidation or salvage is favorable compared to patients who were unable to receive high-dose therapy.Öğe A Real-life Turkish experience of venetoclax treatment in high-risk myelodysplastic syndrome and acute myeloid leukemia(Elsevier Inc., 2021) Gemici, Ali Ihsan; Özkalemkas, Fahir; Doğu, Mehmet Hilmi; Tekinalp, Atakan; Alacacıoğlu, İnci; Güney, Tekin; Ince, Idris; Gedük, AyferIntroduction: Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) in combination with either low-dose cytarabine (ARA-C) or hypomethylating agents. We aimed to collect and share data among the efficacy and safety of venetoclax both as a monotherapy or in combination with other drugs used to treat high-risk MDS or AML. Materials and Methods: A total of 60 patients with a median age of 67 (30-83) years from 14 different centers were included in the final analysis. Thirty (50%) of the patients were women; 6 (10%) of the 60 patients were diagnosed with high-risk MDS and the remaining were diagnosed with AML. Results: The best objective response rate (complete remission [CR], complete remission with incomplete hematological recovery (CRi), morphological leukemia-free state [MLFS], partial response [PR]) was 35% in the entire cohort. Best responses achieved during venetoclax per patient number were as follows: 7 CR, 1 CRi, 8 MLFS, 5 PR, and stable disease. Median overall survival achieved with venetoclax was 5 months in patients who relapsed and not achieved in patients who were initially treated with venetoclax. Nearly all patients (86.7%) had experienced a grade 2 or more hematologic toxicity. Some 36.7% of these patients had received granulocyte colony stimulating factor (GCSF) support. Infection, mainly pneumonia (26.7%), was the leading nonhematologic toxicity, and fatigue, diarrhea, and skin reactions were the others reported. Conclusion: Our real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML.Öğe The real-world experience with single agent ibrutinib in relapsed/refractory CLL(Elsevier, 2021) Akpınar, Seval; Doğu, Mehmet Hilmi; Çelik, Serhat; Ekinci, Ömer; Yönal Hindilerden, İpek; Dal, Mehmet Sinanntroduction/background: The emergence of novel agents targeting the B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We evaluated the safety and efficacy of single-agent ibrutinib in relapsed/refractory CLL in real-world settings. Patients/methods: A total of 200 relapsed/refractory CLL patients with a median age of 68 were included in this retrospective, multicenter, non-interventional study. Data of the study were captured from the patient charts of the participating centers. Results: The median for lines of previous chemotherapy was 2 (1-6); 62 (31.8%) patients had del17p and/or p53 mutations (del17p+/p53mut). Of the study group, 146 (75%) patients achieved at least PR, while 16 (8.7%) patients discontinued ibrutinib due to TEA. The most common drug-related adverse events were neutropenia (n: 31; 17.4%) and thrombocytopenia (n: 40; 22.3%), which were ? grade 3 in 9 (5%) and 5 (3.9%) patients, respectively. Pneumonia (n: 42; 23.7%) was the most common nonhematologic TEA. Atrial fibrillation (n: 5; 2.8%) and bleeding (n: 11; 6.3%) were relatively rare during the study period. Within a median follow-up period of 17 (1-74) months, 42 (21%) patients died. The estimated median OS of the study cohort was 52 months. Only the response to ibrutinib (CR/PR vs. SD/PD) was significantly associated with OS.Öğe Relaps/refrakter lenfoma (mantle hücreli lenfoma hariç) hastalarında lenalidomid bazlı tedavi sonuçları: Çok merkezli sonuçlar(TR- Dizin, 2021) Doğu, Mehmet Hilmi; Serin, İstemi; Gemici, Ali Ihsan; Karışmaz, Abdülkadir; Turgut, BurhanAmaç: Lenfomalar, çoğunlukla B hücre kökenli heterojen bir hastalık grubunu temsil eder. Lenalidomid, kemo-immünoterapötik ajanlara talidomidin yapısal bir analoğu olarak dahil edilmiştir. Bu çalışmada amaç, mantle hücreli lenfoma dışı lenfomalarda, lenalidomid ile ilgili gerçek yaşam verilerimizi ortaya çıkarmaktır. Hastalar ve Yöntem: Ocak 2018- Ocak 2020 tarihleri arasında lenfoma tanısı alan hastalar geriye dönük olarak incelendi. Lenalidomid kombine rejimleri şu şekilde gruplandırılmıştır: Lenalidomi -deksametazon (Len-D); lenalidomid-bendamustin (Len-B); lenalidomid-rituksimab (Len-R). Bulgular: On beş (%60.9) hasta Len-D, 6 (%30.4) hasta Len-B ve 2 (%8.7) hasta Len-R aldı. En yaygın yanıt 13 (%56.5) hasta ile progresif hastalık idi, sadece 2 (%8.7) hastada tam yanıt vardı. Sonuç: Lenalidomid, diffüz büyük B hücreli lenfomalar (DBBHL), folliküler lenfoma (FL) ve indolen relaps/refrakter lenfomalar ile relaps/refrakter Hodgkin lenfomada (HL) yeni tedavi seçenekleri arasında yer almaktadır.Öğe Serum Aspergillus galactomannan lateral flow assay for the diagnosis of invasive aspergillosis: a single center study(WILEY, 2021) Serin, Istemi; Doğu, Mehmet HilmiBackground: Aspergillus species meet the most important group of invasive fungal diseases (IFD) in immunosuppressed patients. Galactomannan is a polysaccharide antigen located in the wall structure of Aspergillus. The most commonly used method for antigen detection is enzymelinked immunoassay (ELISA). Aspergillus galactomannan Lateral Flow Assay (LFA) constitutes one of the new methods in the diagnosis of invasive aspergillosis (IA). The goal of this study is to demonstrate efficacy of LFA in our patients and to compare it to synchronous ELISA results. Methods: Galactomannan antigen was examined using both LFA and ELISA in serum samples taken from patients who were followed up in our hematology clinic. All patients are classified in subgroups as "proven", "probable", and “possible" patients according to the last EORTC / MSG guideline. Patients who met the “proven" IA criteria were included in the study as the gold standard. Results: A total of 87 patients were included in the study. Majority of patients had acute myeloid leukemia (AML) (56.3%). Eleven (12.6%) were in "proven" IA group. LFA test showed a superior diagnostic performance compared to ELISA (LFAAUC = 0.934 vs ELISAAUC = 0.545; p <0.001). The LFA had a sensitivity of 90.9%, and a specificity of 90.8% for "0.5 ODI" in predicting IA (PPV = 55.8%; NPV = 98.6%; p <0.001). Conclusion: The most important finding of this study is that the specificity of LFA was found to be higher for cut-off value of 0.5. It is recommended to combine the methods in many studies to provide a better early diagnosis for IA.Öğe The use of hypomethylating agents in hematologic malignancies: treatment peferences and result(International Journal of Hematologi Oncology, 2021) Doğu, Mehmet Hilmi; Serin, İstemiAim: The objective of this article was to compare the efficiency of azacitidine (AZA) and decitabine (DAC) in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) who are not suitable for high-dose chemotherapy. Materials and methods: MDS and AML patients who were treated with hypomethylating agents (HMAs) between January 2005 and 2020 were evaluated retrospectively. Results: No statistically significant difference was found between the patients who received AZA or DAC in AML patients. In MDS group, the rate of patients who achieved remission was statistically significantly higher in patients who received DAC (p = 0,032). Conclusion: The advantage in terms of response for MDS and no survival difference between AZA and DAC for AML and MDS patients will be an important contribution to the literature. First draft submitted: 24 August 2020; Accepted for publication: 6 September 2021; Published online: 12 November 2021
